Neil Gregory Almstead, serving as the Chief Technical Operations Officer at PTC Therapeutics, Inc. (NASDAQ:PTCT), executed a transaction involving the sale of $693,151 worth of the company's common stock on June 26, 2026. The shares were liquidated at prices ranging from $85.23 to $85.26 per share. This sale followed the exercise of stock options totaling 8,130 shares. Mr. Almstead acquired these shares at an exercise price of $38.10 per share, resulting in a total cost of $309,753. Both the option exercises and the subsequent sales were conducted under a Rule 10b5-1 trading plan that Mr. Almstead adopted on November 11, 2025. Following these transactions, Mr. Almstead directly holds 60,137 shares of PTC Therapeutics common stock, with an additional 2,737 shares held indirectly by his spouse.
The insider sale occurs as PTCT stock trades near its 52-week high of $87.50, following a strong 67% return over the past year. According to InvestingPro analysis, the stock appears slightly overvalued at current levels, which may have influenced the timing of this planned transaction. For investors seeking deeper insights into PTCT's valuation and future prospects, InvestingPro offers 11 additional exclusive tips and comprehensive analysis through its Pro Research Report, available for PTCT and 1,400+ other US equities.
In other recent news, PTC Therapeutics reported robust earnings for the first quarter of 2026, significantly outperforming analyst expectations. The company achieved an earnings per share (EPS) of -$0.03, a notable improvement over the forecasted -$0.46. Additionally, PTC Therapeutics reported revenues of $273 million, surpassing the anticipated $224.08 million. In the realm of analyst ratings, Jefferies upgraded PTC Therapeutics to Buy from Hold, citing optimism about Sephience's future revenue potential. Similarly, TD Cowen also upgraded the stock to Buy, acknowledging the company's strategic progress and early results from a new product launch. BofA Securities maintained its Buy rating, highlighting the momentum of the Sephience launch and the potential for over $2 billion in global peak sales. These recent developments indicate a positive outlook from several analyst firms regarding PTC Therapeutics' future performance.
PTC Therapeutics Follow Analyze PTCT Included in our AI-picked strategies Review strategies 81.57 0.00 (0.00%) Closed 15:59:59 USD 81.51 -0.06 (-0.07%) After Hours 16:56:10 1D 1W 1M 6M 1Y 5Y Max Created with Highcharts 11.4.8 14:00 15:00 16:00 17:00 18:00 19:00 81 82 83 Analyze PTCT This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. See the trade on PTCT, but can't pull the trigger? Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap - and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time. Try Chart Analysis for PTCT